In order to obtain results from an idea of a clinical study project as registration dossier, CE marking or publication we need a great deal knowledge and specialization in clinical research, as well as the involvement of a large number of professionals specialized in their areas.
This requires a multidisciplinary team that works according to standard operating procedures unique to the entire project, from the protocol design to the final report and subsequent publication.
Experior CRO 360º is a comprehensive service in which we cover any aspect related to clinical research in phase I to phase IV trials, post-marketing studies and studies with medical devices. The difference is the flexibility, since we go out of our way to meet the client’s needs. A flexibility that allows us to work together or separately with the client’s employees creating a fully integrated project team.
This is how Experior becomes to be the ideal partner in Spain.
Years of experience
Planning with the Sponsor.
Establishing the tasks, deadlines and results to obtain.
Drafting of documents and creation of tools (eCRF, eTMF, logistics, etc.) required to obtain expected results in the shortest possible time and with the highest quality.
Study submission procedures.
Obtaining the regulatory authorizations, including the contracts required to start the study in accordance with the current regulations.
Operational development of the study protocol.
Monitoring, pharmacovigilance and data management in real time. Always based on risk.
Exploitation and publication of results.
Performing the planned statistical analyses required for drafting the final reports and the necessary publications.
Experior continues evolving!
We completed the integration process in the NEUCA Capital Group.
From this moment…
• Experior CRO becomes
• Experior SMO becomes
We grow and consolidate without losing our essence.
We put at your service a new agile structure, a global coverage, an organizational
network and a parent company that gives us stability and strength to meet the
needs of commercial and non-commercial studies.
Welcome to a new era!
Because "the best way to predict the future is to build it," and that is where we are.